Pharmacology of Cancer Drugs

Antimetabolites are a class of cancer drugs that interfere with the synthesis or function of essential metabolites, such as DNA, RNA, and proteins, thereby inhibiting cell growth and division.

Alkylating agents are a class of cancer drugs that add alkyl groups to DNA, causing DNA damage and inhibiting cell division.

Topoisomerase inhibitors are a class of cancer drugs that inhibit topoisomerase enzymes, which are responsible for unwinding and relaxing DNA during replication and transcription. By inhibiting topoisomerase, these drugs cause DNA damage and cell death.

Antibiotics are a class of cancer drugs that target microtubules, which are essential for cell division. By inhibiting microtubule function, these drugs prevent cell division and cause cell death.

Antibiotics are a class of cancer drugs that target angiogenesis, which is the formation of new blood vessels. By inhibiting angiogenesis, these drugs cut off the blood supply to tumors, causing them to shrink and die.

Immunotherapy is a class of cancer drugs that targets the immune system. These drugs work by either stimulating the immune system to recognize and attack cancer cells or by suppressing the immune system to prevent it from attacking healthy cells.

Alkylating agents are known to cause a variety of side effects, including nausea and vomiting, hair loss, and bone marrow suppression.

Antimetabolites are known to cause a variety of side effects, including nausea and vomiting, diarrhea, and skin rash.

Topoisomerase inhibitors are known to cause a variety of side effects, including nausea and vomiting, diarrhea, and hair loss.

Immunotherapy is known to cause a variety of side effects, including nausea and vomiting, diarrhea, and skin rash.

mTOR inhibitors are a class of cancer drugs that target the PI3K/AKT/mTOR pathway, which is involved in cell growth, proliferation, and survival. By inhibiting mTOR, these drugs block the growth and spread of cancer cells.

Tyrosine kinase inhibitors are a class of cancer drugs that target the BCR-ABL fusion protein, which is found in chronic myeloid leukemia (CML). By inhibiting the BCR-ABL fusion protein, these drugs block the growth and spread of CML cells.

HER2 inhibitors are a class of cancer drugs that target the HER2 protein, which is overexpressed in some types of breast cancer. By inhibiting the HER2 protein, these drugs block the growth and spread of breast cancer cells.

Immune checkpoint inhibitors are a class of cancer drugs that target the PD-1/PD-L1 pathway, which is involved in regulating the immune system. By inhibiting the PD-1/PD-L1 pathway, these drugs release the brakes on the immune system, allowing it to recognize and attack cancer cells.